ANI Pharmaceuticals
ANIP
138 hedge funds and large institutions have $412M invested in ANI Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 33 increasing their positions, 50 reducing their positions, and 12 closing their positions.
125% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 12
123% more capital inflows, than outflows
Capital inflows: $55.6M | Capital outflows: $25M
10% more funds holding
Funds holding: 125 → 138 (+13)
3.69% more ownership
Funds ownership: 55.72% → 59.4% (+3.7%)
8% less call options, than puts
Call options by funds: $718K | Put options by funds: $778K
34% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 50
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Rubric Capital Management (New York)
New York
|
+$11.5M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$4.39M |
| 3 |
PFC
Phocas Financial Corp
Alameda,
California
|
+$3.19M |
| 4 |
Great Lakes Advisors
Chicago,
Illinois
|
+$2.2M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FWSM
First Wilshire Securities Management
Pasadena,
California
|
-$6.54M |
| 2 |
Kennedy Capital Management
St Louis,
Missouri
|
-$3.28M |
| 3 |
Emerald Advisers
Leola,
Pennsylvania
|
-$2.94M |
| 4 |
BlackRock
New York
|
-$1.77M |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$1.13M |
ANIP Hedge Fund Activity: Q1 2023 in Review
138 of the 6,287 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q1 2023, worth a combined $412M — up 5.2% from $391M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new ANIP positions and 12 closed out — a net gain of 15 holders — while 33 added to existing stakes and 50 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $11.5M. The largest seller was First Wilshire Securities Management, cutting an estimated $6.54M.
- 138 institutional investors held ANI Pharmaceuticals (ANIP) as of Q1 2023, up from 125 in Q4 2022.
- Funds reported $412M of ANI Pharmaceuticals stock for Q1 2023, up 5.2% quarter-over-quarter.
- 27 funds opened new ANI Pharmaceuticals positions in Q1 2023 and 12 closed out, a net change of +15 holders.
- The largest ANI Pharmaceuticals buyer in Q1 2023 was Rubric Capital Management (New York), an estimated $11.5M added.
- The largest ANI Pharmaceuticals seller in Q1 2023 was First Wilshire Securities Management, an estimated $6.54M sold.
Based on aggregated 13F filings for Q1 2023.